drugset / Trial / NCT02255032

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032

Phase 2 Completed 22 enrolled Clearside Biomedical, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectious uveitis.

Timeline

Start
2014-10
Primary completion
2015-12
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 0.8 mg Other
Subject Triamcinolone Acetonide Other / unclassified 4 mg Other